Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.15
- Piotroski Score 4.00
- Grade Buy
- Symbol (GIPR)
- Company Generation Income Properties, Inc.
- Price $1.87
- Changes Percentage (3.89%)
- Change $0.07
- Day Low $1.77
- Day High $1.89
- Year High $4.64
Generation Income Properties (GIP) is a Real Estate Investment Trust based in Tampa, Florida that specializes in acquiring a diversified portfolio of high quality single tenant properties. Our portfolio consists of office, industrial and retail assets across the United States occupied by primarily investment grade credit tenants.
- Last Earnings 06/03/2024
- Ex-Dividend for 5/16 Dividend 06/14/2024
- Dividend Payable 06/28/2024
- Today N/A
- Next Earnings (Estimated) 03/07/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.61
- Trailing P/E Ratio -1.62
- Forward P/E Ratio -1.62
- P/E Growth -1.62
- Net Income $-5,717,262
Income Statement
Quarterly
Annual
Latest News of GIPR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Why Generation Income Properties, Inc. (GIPR) is the Best Penny Stock with a Low PE Ratio
The article discusses the potential of Generation Income Properties (GIPR) among penny stocks with low PE ratios. Analysts predict a soft landing for the US economy, favoring small-cap stocks due to a...
By Yahoo! Finance | 1 month ago -
Viking's new dual GLP-1R/GIPR agonist expected to start Phase III trials soon
Viking Therapeutics is developing VK2735, a promising dual GLP-1R/GIPR agonist for obesity treatment. Phase II results show significant weight loss potential, positioning it as a competitor to Eli Lil...
By Yahoo! Finance | 3 months ago
